GCKR — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL15665	1.00	20/20
SCHEMBL15888	1.00	20/20
SCHEMBL16134	1.00	20/20
SCHEMBL17418	1.00	20/20
SCHEMBL16608	0.80	20/20
SCHEMBL15853	0.78	20/20
SCHEMBL15672	1.00	19/20
SCHEMBL15961	1.00	19/20
SCHEMBL16452	1.00	19/20
SCHEMBL16609	1.00	19/20
SCHEMBL17090	1.00	19/20
SCHEMBL17260	1.00	19/20
Hydrochloric Acid (SCHEMBL16029)	0.98	19/20
Hydrochloric Acid (SCHEMBL16325)	0.98	19/20
Hydrochloric Acid (SCHEMBL17254)	0.98	19/20
Hydrochloric Acid (SCHEMBL17118)	0.98	19/20
Hydrochloric Acid (SCHEMBL17128)	0.98	19/20
SCHEMBL16900	0.83	19/20
SCHEMBL16915	0.83	19/20
SCHEMBL16525	0.81	19/20

Clinical trials — most relevant to GCKR by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Liraglutide Actions on the Liver: Effects on Glucose Phosphorylation	PHASE4	WITHDRAWN
Acute Effects of an Oral Fat Load on Skeletal Muscle and Hepatic Insulin Sensitivity	PHASE4	COMPLETED
The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway	PHASE4	COMPLETED
Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)	PHASE4	COMPLETED
Study To Evaluate Beta Cell Function and Glycemic Outcome by Intensive Insulin Therapy	PHASE4	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.	PHASE3	COMPLETED
HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes	PHASE2	RECRUITING
The Assessment of Single-Dose Safety,Tolerability, Pharmacokinetics and Pharmacodynamic of Globalagliatin Hydrochloride	PHASE1	COMPLETED
Multiple Ascending Doses of Globalagliatin Hydrochloride in Type 2 Diabetes Mellitus	PHASE1	COMPLETED
Contribution of Hyperinsulinemia vs. Hyperglycemia to Insulin Resistance in Type 1 Diabetes and Maturity Onset Diabetes of the Young, Type 2 (MODY2)	PHASE1	COMPLETED
Acute Effect of HP-211 (Axulin) on Blood Glucose and Serum Insulin Responses in Healthy Lean and Overweight Humans	PHASE1	COMPLETED
Metformin's Effect on Glucagon-induced Glucose Production and Protein Metabolism.	PHASE1	COMPLETED
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes	nan	COMPLETED
Dried Fruit and Postprandial Glycemia Trial	nan	UNKNOWN
Insulin Resistance in Relation to Hyperthyroidism and Hypothyroidism	nan	UNKNOWN
Effect of Glucagon on Fasting Insulin Secretion and Glucose Metabolism in Subjects Without Type 2 Diabetes	nan	RECRUITING
Hepatic Metabolic Changes in Response to Glucagon Infusion	nan	COMPLETED
Effect of Liraglutide on Clock Genes	nan	UNKNOWN
Role of the Liver in Glucose Homeostasis Using Metabolic Imaging	nan	COMPLETED
Thermogenic Silencer Regulatory Factors in Humans	nan	ACTIVE_NOT_RECRUITING
Effect of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Stimulation on Smoking Consumption in Type 2 Diabetes Patients	nan	ENROLLING_BY_INVITATION
Exercise in Type 1 Diabetes Mellitus	nan	COMPLETED
Insulin Secretion in Diabetes Before and After Glycemic Control	nan	COMPLETED
Efficacy of Physical Exercise on Glucose Control in People With Prediabetes (GLYCEX) - Phase II	nan	UNKNOWN
Effect of Meal Timing in T2D on Hepatocytes SRIT1 and Clock Genes	nan	UNKNOWN
Specificities of Atypical Non AutoImmune Diabetes (ANAID) in the French West Indies	nan	NOT_YET_RECRUITING
Observational Study of Blood Glucose Levels and Gut Microbiota in Healthy Individuals	nan	COMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a GCKR binder may also engage these)

Protein	Name	Similarity
Q07071	—	1.000	Q07071 →
Q91X44	—	0.999	Q91X44 →
Q91754	—	0.994	Q91754 →
Q41140	—	0.987	Q41140 →
Q9S7S2	—	0.986	Q9S7S2 →
HMGCR	3-hydroxy-3-methylglutaryl-coenzyme A reductase	0.985	landscape →
Q3SYT1	—	0.985	Q3SYT1 →
Q8TGA1	—	0.984	Q8TGA1 →
P06623	—	0.984	P06623 →
Q9SYP2	—	0.984	Q9SYP2 →
Q1W675	—	0.984	Q1W675 →
O59713	—	0.984	O59713 →
Q29512	—	0.984	Q29512 →
Q6GPQ5	—	0.984	Q6GPQ5 →
CAD	Multifunctional protein CAD	0.984	landscape →
Q5XI69	—	0.984	Q5XI69 →
A6NC97	—	0.984	A6NC97 →
P51639	—	0.983	P51639 →
Q8IUF1	—	0.983	Q8IUF1 →
Q9C9K3	—	0.983	Q9C9K3 →
Q822J8	—	0.983	Q822J8 →
P07258	—	0.983	P07258 →
Q8K3V4	—	0.983	Q8K3V4 →
Q6RJS2	—	0.982	Q6RJS2 →
Q08BC6	—	0.982	Q08BC6 →
Q6PE54	—	0.982	Q6PE54 →
P08955	—	0.982	P08955 →
P14714	—	0.982	P14714 →
Q9SU87	—	0.982	Q9SU87 →
Q5BJS0	—	0.982	Q5BJS0 →